

Ref: FOI/CAD/ID 3235

**Please reply to:**  
FOI Administrator  
Trust Management  
Service Centre  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

23 May 2016

### **Freedom of Information Act 2000**

I am writing in response to your follow up request for information made under the Freedom of Information Act 2000 in relation to Chronic Myeloid Leukaemia (CML) 2015.

*Following your reply, please could you provide the information requested in sections 2, 3 and 5 regardless of indication.*

1. *In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?*
2. *Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?*
  - *Dasatinib (Sprycel)*
  - *Imatinib (Glivec)*
  - *Nilotinib (Tasigna)*
  - *Ponatinib (Iclusig)*
  - *Bosutinib (Bosulif)*
3. *If possible, of these patients on a TKI, how many have had treatment with a previous TKI?*
4. *In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?*
5. *Of these patients how many are currently being treated with each of the following TKIs?*
  - *Dasatinib (Sprycel)*
  - *Imatinib (Glivec)*
  - *Nilotinib (Tasigna)*
  - *Ponatinib (Iclusig)*
  - *Bosutinib (Bosulif)*

- *Other (i.e. not on a TKI)*

Answers to questions 2, 3 and 5 regardless of indication:

- 2) 35 patients
- 3) 24 patients
- 5) 20 patients